avapro has been researched along with Diabetes Mellitus, Adult-Onset in 145 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 9.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 9.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| "Telmisartan seemed to improve glycaemic and lipid control and metabolic parameters of the metabolic syndrome better than irbesartan." | 9.12 | Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA, 2007) |
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 9.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 9.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux." | 7.01 | Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. ( Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ, 2021) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 6.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 5.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 5.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| "This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk." | 5.14 | Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. ( Franklin, SS; Neutel, JM, 2010) |
| "Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective." | 5.13 | [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008) |
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 5.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "Telmisartan seemed to improve glycaemic and lipid control and metabolic parameters of the metabolic syndrome better than irbesartan." | 5.12 | Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA, 2007) |
| "A post hoc pooled analysis of 2 multicenter, randomized, double-blind, active-controlled force-titration studies assessed the antihypertensive efficacy and tolerability of 7 to 8 weeks' once-daily fixed-dose irbesartan/hydrochlorothiazide (HCTZ) 300/25 mg in 796 stage 1 or 2 hypertensive patients according to age (65 years or older or younger than 65) (n=121 or 675) and presence or absence of obesity (n=378 or 414), type 2 diabetes (n=99 or 697), and high World Health Organization-defined cardiovascular risk (n=593 or 202)." | 5.12 | The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. ( Bhaumik, A; De Obaldia, ME; Lapuerta, P; Neutel, JM; Weir, MR, 2007) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 5.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension." | 4.84 | Irbesartan: a review of its use in hypertension and diabetic nephropathy. ( Croom, KF; Plosker, GL, 2008) |
| "Irbesartan (Avapro, Aprovel) is a potent and selective angiotensin II subtype 1 receptor antagonist indicated for use in patients with hypertension, including those with type 2 diabetes mellitus and nephropathy." | 4.82 | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. ( Croom, KF; Curran, MP; Goa, KL; Perry, CM, 2004) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Treatment with irbesartan attenuates cardiac inflammation in type 2 diabetic db/db mice, and this effect was probably associated with the suppression of cardiac angiotensin II and NF-κB signaling pathway." | 3.83 | [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice]. ( Gong, WQ; Huang, WC; Liang, Y; Liu, B; Yang, CM; Ye, XL; Zheng, YT, 2016) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "We estimated the cost-effectiveness of irbesartan compared with placebo or amlodipine in the treatment of patients with type 2 diabetes mellitus, hypertension, and overt nephropathy." | 3.72 | The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux." | 3.01 | Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. ( Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ, 2021) |
| "There is a lack of research on the effect of low dose of angiotensin receptor blockers combined with spironolactone, and the effect of high dose of angiotensin receptor blockers alone on the urinary albumin excretion rate (UAER) in elderly patients with early type 2 diabetic nephropathy (DN)." | 2.87 | Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018) |
| "The primary PK parameters - Cmax and AUCτ - were compared to the geometric mean ratios (GMRs) and 90% confidence intervals (90% CIs) that were determined for the combination therapies and monotherapies." | 2.80 | Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. ( Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS, 2015) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "2,739 participants with type 2 diabetes and nephropathy with at least 1 year of blood pressure measurements available." | 2.79 | Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. ( de Zeeuw, D; Dwyer, JP; Forman, JP; Lambers Heerspink, HJ; McMullan, CJ; Parving, HH, 2014) |
| "A total of 45 type 2 diabetic kidney disease patients were enrolled into this prospective study, and were randomly divided into 3 groups: TwHF treatment group (DT, n = 15), irbesartan treatment group (DI, n = 15), and TwHF combined with irbesartan treatment group (DTI, n = 15)." | 2.78 | [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients]. ( Ma, RX; Zhang, W; Zhao, N, 2013) |
| "133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain." | 2.78 | Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. ( Barrio, V; Cachofeiro, V; de Vinuesa, SG; Fernandez Juarez, G; Fernández Vega, F; Goicoechea, M; Gutierrez, E; Luño, J; Nieto, J; Praga, M; Tato, A, 2013) |
| "Treatment of patients with type 2 diabetes with Irbesartan decreased urinary excretion of MG-H1, G-H1 and 3-NT, which may result from decreased exposure to these AGEs." | 2.77 | Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. ( Adaikalakoteswari, A; Parving, HH; Rabbani, N; Rossing, K; Rossing, P; Tarnow, L; Thornalley, PJ, 2012) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 2.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| "We enrolled 43 individuals with type 2 diabetes mellitus." | 2.76 | Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? ( Barkoudah, E; Danser, AH; Fisher, ND; Hollenberg, NK; Moukarbel, GV; Nussberger, J, 2011) |
| "The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-blind trial comparing irbesartan (150 and 300 mg once daily) with placebo." | 2.76 | Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. ( Afzal, S; Andersen, JT; Broedbaek, K; Henriksen, T; Jimenez-Solem, E; Parving, HH; Persson, F; Petersen, M; Poulsen, HE; Rossing, P; Weimann, A, 2011) |
| "A total of 40 normotensive type 2 diabetes patients (mean age 55." | 2.73 | Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes. ( Cetinkalp, SS; Erdogan, MA; Karadeniz, MM; Ozgen, GA; Yilmaz, CO, 2008) |
| " The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information." | 2.72 | Irbesartan (a comprehensive profile). ( Al-Kahtani, HM; Alanazi, Z; Bakheit, AH; Darwish, HW; Darwish, IA, 2021) |
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| "Thirty percent had type 2 diabetes mellitus, 46% had metabolic syndrome, and baseline blood pressure was 154." | 2.71 | The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Neutel, JM; Ofili, EO; Saunders, E; Sowers, JR; Weber, MA, 2005) |
| "In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it." | 2.71 | Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Preti, P; Zoppi, A, 2004) |
| "During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI)." | 2.71 | Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. ( Aguilar, D; Berl, T; Gans, DJ; Goldhaber, SZ; Levey, AS; Lewis, EJ; Lewis, JB; Pfeffer, MA; Porush, JG; Rouleau, JL, 2004) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "Treatment with olmesartan (n=9) significantly increased EPCs from 231+/-24 to 465+/-71 per high-power field (P<0." | 2.71 | Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. ( Bahlmann, FH; de Groot, K; Fliser, D; Haller, H; Hertel, B; Mueller, O, 2005) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg." | 2.71 | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world." | 2.69 | The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. ( Anzalone, DA; Atkins, RC; Clarke, WR; Hunsicker, LG; Lewis, EJ; Ritz, E; Rodby, RA; Rohde, RD, 2000) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "The mean +/- SD cumulative incidence of ESRD was reduced by 8." | 2.44 | Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. ( Palmer, AJ; Ray, JA; Valentine, WJ, 2007) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "Telmisartan is an angiotensin Type 1 (AT(1))-receptor antagonist being used in the treatment of hypertension." | 2.42 | Telmisartan - killing two birds with one stone. ( Doggrell, SA, 2004) |
| "Proteinuria was reduced on average by 33% in the irbesartan group as compared with 6% in the amlodipine group and 10% in the placebo group." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "Type 2 diabetes is increasing globally and is a major cause of conditions such as cardiovascular disease, retinopathy and nephropathy." | 2.42 | What is the impact of PRIME on real-life diabetic nephropathy? ( Ruilope, LM, 2004) |
| "Irbesartan treatment of patients with type 2 diabetes, hypertension, and microalbuminuria may lead to major improvements in long-term patient outcomes, with substantial cost savings as an added bonus to third party payers." | 2.42 | Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. ( Palmer, AJ; Rodby, RA, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "Irbesartan and creatinine clearance in NIDDM patients." | 2.40 | Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. ( Hollenberg, NK, 1997) |
| "Myocardial fibrosis is one of the serious pathological changes, so investigating the pathogenesis of myocardial fibrosis has the significant value." | 1.51 | Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model. ( Guanjun, Z; Heng, Z; Hongwei, Y; Jie, H; Jie, T; Junfeng, H; Qin, G; Ruiping, C; Xingyu, L; Yingyan, F; Zhenghong, L, 2019) |
| "Data from patients with type 2 diabetes and microalbuminuria (n = 49) treated with irbesartan 300 mg/day were used for discovery." | 1.43 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. ( Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P, 2016) |
| "Bilirubin was inversely associated with the renal end point in RENAAL independent of age, sex, race, BMI, smoking, total cholesterol, diastolic blood pressure, HbA1c, treatment, estimated glomerular filtration rate, albumin-to-creatinine ratio, and AST." | 1.40 | Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. ( Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ, 2014) |
| "T2DM rats were induced by fed with high-sucrose-high-fat diet combined with a low dose of streptozocin." | 1.38 | [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model]. ( Li, YS; Liu, LQ; Ma, RX; Xu, Y; Zhang, J, 2012) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "Cumulative incidence of ESRD, time to onset of ESRD, life expectancy (LE), quality-adjusted life years (QALY) and costs were projected over 25 years for 1,000 simulated patients, from a third party payer perspective." | 1.33 | [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]. ( Lehnert, H; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S; Valentine, WJ, 2006) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared to amlodipine and control in the Spanish setting." | 1.32 | [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]. ( Annemans, L; de Alvaro, F; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "This epidemic growth in ESRD has led to skyrocketing utilization of health care resources." | 1.32 | Pharmacoeconomic challenges in the management of diabetic nephropathy. ( Rodby, RA, 2004) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared with amlodipine and control." | 1.32 | An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. ( Annemans, L; Cordonnier, DJ; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2003) |
| "As obesity is a common finding in diabetic individuals, and obesity has been linked to an increase in plasma angiotensinogen levels, we enrolled diabetic subjects with a wide range of body mass index (BMI) for this study." | 1.31 | Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. ( Fisher, ND; Hollenberg, NK; Laffel, LM; Lansang, MC; Osei, SY; Price, DA, 2002) |
| "Patients with Type 2 diabetes and nephropathy should receive either an AT(1) antagonist or the angiotensin converting enzyme inhibitor ramipril to ensure renoprotection." | 1.31 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. ( Doggrell, SA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.38) | 18.2507 |
| 2000's | 104 (71.72) | 29.6817 |
| 2010's | 35 (24.14) | 24.3611 |
| 2020's | 4 (2.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Tostivint, I | 1 |
| Xu, L | 1 |
| Huang, J | 1 |
| Gambotti, L | 1 |
| Boffa, JJ | 1 |
| Yang, M | 1 |
| Wang, L | 2 |
| Sun, Z | 1 |
| Chen, X | 2 |
| Liou-Schischmanoff, A | 1 |
| Baumelou, A | 1 |
| Ma, T | 1 |
| Lu, G | 1 |
| Li, L | 2 |
| Chen, D | 1 |
| Piéroni, L | 1 |
| Liu, B | 2 |
| Qin, X | 1 |
| He, W | 1 |
| Wang, Y | 2 |
| Gu, HF | 1 |
| Sun, W | 1 |
| Wang, H | 1 |
| Lu, Z | 2 |
| Li, Y | 2 |
| Liu, T | 1 |
| Zhao, L | 1 |
| Gao, T | 1 |
| Lu, X | 2 |
| Gao, B | 1 |
| Piazza, M | 1 |
| Hanssen, NMJ | 1 |
| Persson, F | 8 |
| Scheijen, JL | 1 |
| van de Waarenburg, MPH | 1 |
| van Greevenbroek, MMJ | 1 |
| Rossing, P | 12 |
| Hovind, P | 5 |
| Stehouwer, CDA | 1 |
| Parving, HH | 24 |
| Schalkwijk, CG | 3 |
| Darwish, IA | 1 |
| Darwish, HW | 1 |
| Bakheit, AH | 1 |
| Al-Kahtani, HM | 1 |
| Alanazi, Z | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Ye, XL | 1 |
| Huang, WC | 1 |
| Zheng, YT | 1 |
| Liang, Y | 1 |
| Gong, WQ | 1 |
| Yang, CM | 1 |
| Chen, Y | 1 |
| Liu, P | 1 |
| Zhang, F | 1 |
| Hongwei, Y | 1 |
| Ruiping, C | 1 |
| Yingyan, F | 1 |
| Guanjun, Z | 1 |
| Jie, H | 1 |
| Xingyu, L | 1 |
| Jie, T | 1 |
| Zhenghong, L | 1 |
| Qin, G | 1 |
| Junfeng, H | 1 |
| Heng, Z | 1 |
| Garrelds, IM | 1 |
| Danser, AH | 3 |
| Ma, RX | 2 |
| Zhao, N | 1 |
| Zhang, W | 1 |
| Gialama, F | 1 |
| Maniadakis, N | 1 |
| Lambers Heerspink, HJ | 7 |
| Weldegiorgis, M | 1 |
| Inker, LA | 1 |
| Gansevoort, R | 1 |
| Dwyer, JP | 2 |
| Mondal, H | 1 |
| Coresh, J | 1 |
| Greene, T | 1 |
| Levey, AS | 2 |
| de Zeeuw, D | 12 |
| Riphagen, IJ | 1 |
| Deetman, PE | 1 |
| Bakker, SJ | 3 |
| Navis, G | 1 |
| Cooper, ME | 2 |
| Lewis, JB | 8 |
| Hull, TD | 1 |
| Agarwal, A | 1 |
| McMullan, CJ | 1 |
| Forman, JP | 1 |
| Choi, HY | 1 |
| Lim, HS | 1 |
| Kim, YH | 1 |
| Jeon, HS | 1 |
| Kim, MJ | 1 |
| Lee, SH | 1 |
| Jung, JH | 1 |
| Lee, YK | 1 |
| Kim, HJ | 1 |
| Bae, KS | 1 |
| Liu, X | 1 |
| Xu, Q | 1 |
| Wang, X | 1 |
| Zhao, Z | 1 |
| Zhang, L | 1 |
| Zhong, L | 1 |
| Kang, W | 1 |
| Zhang, Y | 1 |
| Ge, Z | 1 |
| Schievink, B | 1 |
| Schutte, E | 1 |
| Lutgers, HL | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Gansevoort, RT | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 2 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Chen, XW | 1 |
| Du, XY | 1 |
| Wang, YX | 1 |
| Wang, JC | 1 |
| Liu, WT | 1 |
| Chen, WJ | 1 |
| Li, HY | 1 |
| Peng, FF | 1 |
| Xu, ZZ | 1 |
| Niu, HX | 1 |
| Long, HB | 1 |
| Pena, MJ | 1 |
| Heinzel, A | 1 |
| Dallmann, G | 1 |
| Rossing, K | 4 |
| Andersen, S | 6 |
| Mayer, B | 1 |
| Heerspink, HJ | 1 |
| Zhong, J | 1 |
| Gong, W | 1 |
| Lu, L | 1 |
| Chen, J | 1 |
| Li, H | 1 |
| Liu, W | 1 |
| Liu, Y | 1 |
| Wang, M | 1 |
| Hu, R | 1 |
| Long, H | 1 |
| Wei, L | 1 |
| Stehouwer, CD | 4 |
| Tarnow, L | 3 |
| Croom, KF | 2 |
| Plosker, GL | 1 |
| Cetinkalp, SS | 1 |
| Karadeniz, MM | 1 |
| Erdogan, MA | 1 |
| Ozgen, GA | 1 |
| Yilmaz, CO | 1 |
| Belousov, IuB | 1 |
| Shestakova, MV | 1 |
| Belousov, DIu | 1 |
| Lewin, AJ | 1 |
| Weir, MR | 2 |
| Chen, HB | 1 |
| Lu, JX | 1 |
| Li, Q | 1 |
| Bao, YQ | 1 |
| Tang, JL | 1 |
| Lu, HJ | 1 |
| Xiang, KS | 1 |
| Jia, WP | 1 |
| Reinhard, H | 1 |
| Juhl, T | 1 |
| Schalkwijk, C | 2 |
| Boomsma, F | 2 |
| Frandsen, E | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Parhofer, KG | 1 |
| Birkeland, KI | 1 |
| DeFronzo, R | 1 |
| Del Prato, S | 1 |
| Bhaumik, A | 2 |
| Ptaszynska, A | 1 |
| Skalli, S | 1 |
| Wion-Barbot, N | 1 |
| Baudrant, M | 1 |
| Lablanche, S | 1 |
| Benhamou, PY | 1 |
| Halimi, S | 1 |
| Franklin, SS | 1 |
| Neutel, JM | 5 |
| Mischak, H | 1 |
| Zürbig, P | 1 |
| Rabbani, N | 1 |
| Adaikalakoteswari, A | 1 |
| Thornalley, PJ | 1 |
| Engelen, L | 1 |
| Ferreira, I | 1 |
| Teerlink, T | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 4 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Broedbaek, K | 1 |
| Henriksen, T | 1 |
| Weimann, A | 1 |
| Petersen, M | 1 |
| Andersen, JT | 1 |
| Afzal, S | 1 |
| Jimenez-Solem, E | 1 |
| Poulsen, HE | 1 |
| Hellemons, ME | 1 |
| Yang, H | 1 |
| Nyby, MD | 1 |
| Ao, Y | 1 |
| Chen, A | 1 |
| Adelson, DW | 1 |
| Smutko, V | 1 |
| Wijesuriya, J | 1 |
| Go, VL | 1 |
| Tuck, ML | 1 |
| Hollenberg, NK | 3 |
| Fisher, ND | 2 |
| Nussberger, J | 1 |
| Moukarbel, GV | 1 |
| Barkoudah, E | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Li, YS | 1 |
| Liu, LQ | 1 |
| Fernandez Juarez, G | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| de Vinuesa, SG | 1 |
| Praga, M | 1 |
| Goicoechea, M | 1 |
| Cachofeiro, V | 1 |
| Nieto, J | 1 |
| Fernández Vega, F | 1 |
| Tato, A | 1 |
| Gutierrez, E | 1 |
| Malishevskiĭ, MV | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 1 |
| Price, DA | 1 |
| Lansang, MC | 1 |
| Osei, SY | 1 |
| Laffel, LM | 1 |
| Suzuki, H | 1 |
| Sasso, FC | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Iafusco, D | 1 |
| Salvatore, T | 1 |
| D'Ambrosio, R | 1 |
| Torella, R | 1 |
| Cozzolino, D | 1 |
| Sugimoto, T | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Eberhard, R | 1 |
| Dikow, R | 1 |
| Christensen, PK | 1 |
| Hansen, HP | 1 |
| Hunsicker, LG | 7 |
| Pfeffer, MA | 2 |
| Porush, JG | 2 |
| Rouleau, JL | 2 |
| Drury, PL | 1 |
| Esmatjes, E | 1 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 2 |
| Vanhille, P | 1 |
| Wiegmann, TB | 2 |
| Wolfe, BM | 1 |
| Locatelli, F | 2 |
| Goldhaber, SZ | 2 |
| Lewis, EJ | 8 |
| Biesenbach, G | 1 |
| Janko, O | 1 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Postma, MJ | 1 |
| Kruidhof, H | 1 |
| de Jong-van den Berg, LT | 1 |
| Rodby, RA | 12 |
| Chiou, CF | 1 |
| Borenstein, J | 1 |
| Smitten, A | 1 |
| Sengupta, N | 1 |
| Palmer, AJ | 13 |
| Roze, S | 10 |
| Annemans, L | 7 |
| Simon, TA | 1 |
| Chen, RS | 1 |
| Lamotte, M | 4 |
| Cordonnier, DJ | 1 |
| González-Albarrán, O | 1 |
| Gómez, O | 1 |
| Ruiz, E | 1 |
| Vieitez, P | 1 |
| García-Robles, R | 1 |
| Bröchner-Mortensen, J | 2 |
| Lehnert, H | 5 |
| Bramlage, P | 5 |
| Pittrow, D | 3 |
| Kirch, W | 4 |
| Ritz, E | 4 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Foreman, BH | 1 |
| Chambliss, ML | 1 |
| Mugellini, A | 2 |
| Preti, P | 1 |
| Zoppi, A | 1 |
| Corradi, L | 1 |
| Fogari, E | 3 |
| Derosa, G | 5 |
| Fogari, R | 5 |
| Curran, MP | 1 |
| Goa, KL | 1 |
| Perry, CM | 1 |
| Kaiser, T | 1 |
| Florack, C | 1 |
| Sawicki, PT | 1 |
| Schute, LL | 1 |
| Aguilar, D | 1 |
| Gans, DJ | 1 |
| Lapuerta, P | 4 |
| Chen, R | 4 |
| Gabriel, S | 3 |
| Carita, P | 3 |
| de Alvaro, F | 3 |
| Ceriello, A | 3 |
| Assaloni, R | 2 |
| Da Ros, R | 2 |
| Maier, A | 2 |
| Quagliaro, L | 2 |
| Piconi, L | 2 |
| Esposito, K | 2 |
| Giugliano, D | 2 |
| Schunkert, H | 1 |
| Doggrell, SA | 3 |
| Atkins, RC | 4 |
| Briganti, EM | 1 |
| Braden, G | 1 |
| Champion de Crespigny, PJ | 1 |
| DeFerrari, G | 1 |
| Drury, P | 1 |
| Bahlmann, FH | 1 |
| de Groot, K | 1 |
| Mueller, O | 1 |
| Hertel, B | 1 |
| Haller, H | 1 |
| Fliser, D | 1 |
| Cicero, AF | 4 |
| Gaddi, A | 1 |
| Ciccarelli, L | 2 |
| Friedman, AN | 2 |
| Selhub, J | 2 |
| Bostom, AG | 2 |
| Schjoedt, KJ | 1 |
| Jensen, BR | 1 |
| Huang, XS | 1 |
| Zhou, YL | 1 |
| Chen, JY | 1 |
| Lin, SG | 1 |
| Schmieder, RE | 2 |
| Krekler, M | 2 |
| Matos, JP | 1 |
| de Lourdes Rodrigues, M | 1 |
| Ismerim, VL | 1 |
| Boasquevisque, EM | 1 |
| Genelhu, V | 1 |
| Francischetti, EA | 1 |
| Strutz, F | 1 |
| Paar, WD | 1 |
| Saunders, E | 3 |
| Bakris, GL | 2 |
| Cushman, WC | 2 |
| Ferdinand, KC | 2 |
| Ofili, EO | 2 |
| Sowers, JR | 2 |
| Weber, MA | 2 |
| Pershadsingh, HA | 1 |
| Burnier, M | 3 |
| Zanchi, A | 1 |
| Janiak, P | 1 |
| Bidouard, JP | 1 |
| Cadrouvele, C | 1 |
| Poirier, B | 1 |
| Gouraud, L | 1 |
| Grataloup, Y | 1 |
| Pierre, F | 1 |
| Bruneval, P | 1 |
| O'Connor, SE | 1 |
| Herbert, JM | 1 |
| Frei, A | 2 |
| Hess, B | 2 |
| Sharma, AM | 1 |
| Valentine, WJ | 5 |
| Ray, JA | 4 |
| Spinas, GA | 1 |
| Brändle, M | 1 |
| Huang, Z | 2 |
| Jansson, L | 2 |
| Sjöholm, A | 2 |
| Tucker, DM | 1 |
| Laville, M | 1 |
| Muszbek, N | 1 |
| D'Angelo, A | 3 |
| Ragonesi, PD | 2 |
| Piccinni, MN | 1 |
| Pricolo, F | 1 |
| Salvadeo, SA | 2 |
| Ferrari, I | 3 |
| Gravina, A | 3 |
| Fassi, R | 2 |
| Salvadeo, S | 1 |
| Coyle, D | 1 |
| Rodby, R | 1 |
| Soroka, S | 1 |
| Levin, A | 1 |
| Muirhead, N | 1 |
| de Cotret, PR | 1 |
| Palmer, A | 1 |
| De Obaldia, ME | 1 |
| Cable, G | 1 |
| Neutel, J | 1 |
| Busch, M | 1 |
| Franke, S | 1 |
| Wolf, G | 1 |
| Rohde, RD | 2 |
| Stein, G | 1 |
| O'Donnell, MP | 1 |
| Crary, GS | 1 |
| Oda, H | 1 |
| Kasiske, BL | 1 |
| Powell, JR | 1 |
| Keane, WF | 1 |
| Clarke, WR | 2 |
| Anzalone, DA | 1 |
| Bold, KO | 1 |
| Coats, AJ | 1 |
| Pohl, MA | 1 |
| Rohde, R | 1 |
| Gomis, R | 2 |
| Arner, P | 3 |
| Bloomgarden, ZT | 1 |
| Brøchner-Mortensen, J | 1 |
| Kurtzman, NA | 1 |
| Jerums, G | 1 |
| Gilbert, RE | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Walser, M | 1 |
| Motz, E | 1 |
| Swift, PA | 1 |
| MacGregor, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-controlled, Multi-center Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease[NCT03016832] | Early Phase 1 | 414 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)[NCT00317915] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects[NCT01825850] | Phase 1 | 30 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects[NCT01823133] | Phase 1 | 30 participants (Anticipated) | Interventional | 2013-04-30 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipien[NCT00464880] | Phase 1/Phase 2 | 24 participants | Interventional | 2005-09-30 | Completed | ||
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome[NCT00110422] | Phase 4 | 400 participants | Interventional | 2005-11-30 | Completed | ||
| An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus[NCT00660309] | Phase 4 | 45 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| Relation Between Postprandial Lipogram and Coronary Artery Disease Severity[NCT03175393] | 100 participants (Anticipated) | Observational | 2017-07-01 | Recruiting | |||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879] | Phase 4 | 52 participants | Interventional | 2003-09-30 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~The measure of the single dose effect (SDE) for aliskiren and irbesartan was calculated as Day 2 peak - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 10.52 |
| Irbesartan | 10.16 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~The measure of the single dose effect (SDE) for captopril was calculated as Day 1 peak - Day 1 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 1: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 11.29 |
| Irbesartan | 7.41 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~The measure of the single dose effect (SDE) for aliskiren and irbesartan was calculated as Day 2 peak - Day 2 baseline RPF. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 37.18 |
| Irbesartan | 35.88 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~The measure of the single dose effect (SDE) for captopril was calculated as Day 1 peak - Day 1 baseline RPF. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 1: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 43.32 |
| Irbesartan | 40.13 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~This maximum multiple dose effect (MDE_Max) was calculated as Day 15 peak - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 8.69 |
| Irbesartan | 2.96 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~This maximum multiple dose effect (MDE_Max) was calculated as Day 15 peak - Day 2 baseline. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2: Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 24.62 |
| Irbesartan | 24.22 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~This multiple dose effect at steady state (MDE_SS) was calculated as Day 15 baseline - Day 2 baseline GFR. Baseline GFR was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values." (NCT00660309)
Timeframe: Day 2 and Day 15 at Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) .
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | 1.05 |
| Irbesartan | -5.67 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~This multiple dose effect at steady state (MDE_SS) was calculated as Day 15 baseline - Day 2 baseline. Baseline RPF was determined as the median of the -10 minute, -5 minute predose and predose (0 hour) values." (NCT00660309)
Timeframe: Day 2 and Day 15 at Baseline (10 minutes and 5 minutes pre-treatment and 0 hours) .
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -5.67 |
| Irbesartan | -13.08 |
"Glomerular filtration rate (GFR) was measured by the clearance of inulin by autoanalyzer methods.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) was calculated as Day 15 peak - Day 2 peak GFR. Peak GFR was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2 and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -1.71 |
| Irbesartan | -8.68 |
"Renal plasma flow (RPF) was measured by the clearance of para-aminohippurate (PAH) by autoanalyzer methods.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) was calculated as Day 15 peak - Day 2 peak. Peak RPF was obtained using a moving average concept." (NCT00660309)
Timeframe: Day 2 and Day 15: 1, 2, 3, 4 and 5 hours post-dose.
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Aliskiren | -12.74 |
| Irbesartan | -14.67 |
"Retinal blood flow was assessed using the laser Doppler technique. The blood flow in the superior temporal retinal artery in one of the eyes of each study participant was determined.~The Single dose effect of aliskiren or irbesartan was measured as the change/difference between Day 2 and baseline measurements.~The Multiple dose effect of aliskiren or irbesartan wsas measured as the change/difference between Day 15 and Day 2 measurements" (NCT00660309)
Timeframe: Baseline (Day 1), Day 2 and Day 15.
| Intervention | µL/min (Mean) | |
|---|---|---|
| Single dose effect [N=13, 13] | Multiple dose effect [N=13, 11] | |
| Aliskiren | -0.32 | 0.29 |
| Irbesartan | 0.43 | 0.35 |
"The following angiotensin I effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 19] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 2.20 | 0.14 | 0.24 | 0.14 | 1.06 |
| Irbesartan | 1.54 | 0.83 | 2.67 | 2.21 | 2.71 |
"The following angiotensin II effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 19] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.31 | 0.26 | 0.43 | 0.17 | 0.69 |
| Irbesartan | 0.34 | 1.23 | 4.05 | 3.05 | 2.49 |
"The following plasma pro-renin concentration effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 19] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.97 | 0.93 | 1.07 | 1.10 | 1.17 |
| Irbesartan | 1.01 | 0.96 | 1.20 | 1.13 | 1.18 |
"PRA was measured by the trapping method and the following effects assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 baseline / Day 2 baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 1.47 | 0.09 | 0.12 | 0.07 | 0.95 |
| Irbesartan | 1.19 | 1.30 | 3.79 | 3.28 | 2.67 |
"The following plasma renin concentration effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N=21, 19] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 1.18 | 2.53 | 4.41 | 4.81 | 1.93 |
| Irbesartan | 0.92 | 1.04 | 2.35 | 2.06 | 1.91 |
"The following serum aldosterone effects were assessed:~The single dose effect (SDE) for captopril, expressed as the ratio to pre-dose measurement on Day 1, = Day 1, 5 hour / Day 1 Baseline.~SDE for aliskiren and irbesartan = Day 2, 5 hour / Day 2 Baseline.~Steady state trough effect (multiple dose effect at steady state; MDE_SS) = Day 15 Baseline / Day 2 Baseline.~Steady State peak effect (maximum multiple dose effect; MDE_Max) = Day 15, 5 hour / Day 2 Baseline.~Accumulation of peak effect from single dose to multiple dose (MDE_Acc) = Day 15, 5 hour / Day 2, 5 hour." (NCT00660309)
Timeframe: Predose (Baseline) and 5 hours post dose on Days 1, 2 and 15.
| Intervention | ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| SDE after captopril [N=22, 20] | SDE after aliskiren/irbesartan [N=22, 20] | Steady State Trough Effect [N= 21, 19] | Steady State Peak Effect [N= 21, 18] | Accumulation of Peak Effect [N= 21, 18] | |
| Aliskiren | 0.58 | 0.66 | 0.81 | 0.60 | 0.93 |
| Irbesartan | 0.75 | 0.65 | 0.82 | 0.64 | 1.02 |
29 reviews available for avapro and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Irbesartan (a comprehensive profile).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2021 |
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2013 |
Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabe | 2008 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
[Evidence based treatment of diabetic nephropathy].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseas | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2003 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diab | 2004 |
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2004 |
What is the impact of PRIME on real-life diabetic nephropathy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mell | 2004 |
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cost Savings; Diabetes Mellitus, Type 2; H | 2004 |
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl | 2004 |
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Dise | 2005 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Computer Simulation; Costs and Cost Ana | 2007 |
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1997 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Melli | 2001 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
57 trials available for avapro and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial.
Topics: Abelmoschus; Albuminuria; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dou | 2022 |
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chromatography, Liquid; Deoxygluco | 2021 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2018 |
Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Amides; Angiotensinogen; Angiotensins; Antihypertensive Ag | 2013 |
[The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
Topics: Aged; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drugs, Chinese Herbal; | 2013 |
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Ty | 2014 |
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2014 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response | 2015 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response | 2015 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response | 2015 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Topics: Adult; Aged; Albuminuria; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2008 |
Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes M | 2008 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Co | 2008 |
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diver
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Body Mass Index; Body Weight; Cluster Analysis; D | 2008 |
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; D | 2009 |
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, T | 2010 |
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Body Mas | 2010 |
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bendrofl | 2012 |
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes | 2011 |
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Double-Bl | 2011 |
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Doub | 2011 |
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Diab | 2011 |
Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2011 |
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 2013 |
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diabetes Mellit | 2002 |
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressur | 2003 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes M | 2003 |
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dihydropyridine | 2004 |
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.
Topics: Adult; Aged; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropa | 2004 |
Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diab | 2004 |
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Di | 2004 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Count; Diabetes Mellitus, Type 2; | 2005 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, | 2005 |
Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
Topics: Adult; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-B | 2005 |
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; Biphenyl Compounds; C-R | 2005 |
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P | 2005 |
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atheroscler | 2005 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2005 |
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type | 2006 |
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucos | 2006 |
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Topics: Adiponectin; Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2007 |
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Com | 2007 |
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2007 |
Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes Mellitu | 2008 |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphen | 2008 |
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2000 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compou | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Topics: Adult; Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cardiovascula | 2001 |
59 other studies available for avapro and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Virtual Screening of Novel 24-Dehydroxysterol Reductase (
Topics: Animals; Cardiovascular Diseases; Cholesterol; Desmosterol; Diabetes Mellitus, Type 2; Hypertension; | 2023 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
[Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].
Topics: Actins; Angiotensin II; Animals; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Exp | 2016 |
Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.
Topics: Animals; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; | 2019 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Typ | 2014 |
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Ir | 2014 |
Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model.
Topics: Animals; Biphenyl Compounds; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blotting, Western; Diabetes Mellitus, Type 2; | 2016 |
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2016 |
Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Autophagy; Biphenyl Compounds; Dia | 2017 |
The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Sectional Studies; Diabetes | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Ty | 2010 |
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2010 |
Role of brainstem thyrotropin-releasing hormone-triggered sympathetic overactivation in cardiovascular mortality in type 2 diabetic Goto-Kakizaki rats.
Topics: Adrenal Glands; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; | 2012 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
[Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model].
Topics: Animals; Biphenyl Compounds; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Diabetes | 2012 |
Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan.
Topics: Adult; Angiotensin I; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Body Mas | 2002 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
The true overall mortality of unselected nephropathic type 2 diabetic patients with mild to moderate renal insufficiency.
Topics: Antihypertensive Agents; Biphenyl Compounds; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2003 |
[Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes | 2003 |
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete | 2003 |
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Topics: Adult; Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Belgium; Biphenyl Compounds; Ca | 2003 |
Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
Topics: Albuminuria; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2003 |
[Prospective treatment study of irbesartan. Diabetic kidneys regain function].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
[Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2004 |
[Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Germany; Health Care Costs; | 2004 |
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Chann | 2004 |
[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
Topics: Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabe | 2004 |
Pharmacoeconomic challenges in the management of diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Costs and Cos | 2004 |
[A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; | 2004 |
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cost Savings; Diabetes Mel | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2005 |
Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; | 2005 |
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2006 |
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2006 |
[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Computer Simulation; Costs and Cost Ana | 2006 |
Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 2007 |
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Dia | 2006 |
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Comorbidity; Costs and Cos | 2007 |
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Canada; Cost-Benefit Analysis; Diabetes | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2008 |
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Co | 1997 |
[Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2000 |
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Drug companies should not have the final say in the design of clinical trials.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
[Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nep | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2002 |